Related Experiment Video
Updated: Sep 25, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
NN-2211 Novo Nordisk
1Boehringer Ingelheim Pharma GmbH & Co KG, Department of Metabolic Research, Birkendorfer Strasse 65 88397, Biberach an der Riss, Germany. michael.mark@bc.boehringer-ingelheim.com
Abstract:
Novo Nordisk A/S, under license from Scios Inc, is developing NN-2211, a stable analog of the naturally occurring peptide hormone glucagon-like peptide 1 (GLP-1), which stimulates insulin release in response to increases in blood sugar levels, for the potential treatment of type 2 diabetes.
Related Concept Videos
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Diabetic Nephropathy
Diabetic Neuropathy
Type I Diabetes I: Introduction
Type II Diabetes I: Introduction
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
